ClinicalTrials.gov
ClinicalTrials.gov Menu

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01810016
Recruitment Status : Terminated (Low recruitment due to change in standard of care)
First Posted : March 13, 2013
Last Update Posted : March 9, 2018
Sponsor:
Collaborator:
Institute of Cancer Research, United Kingdom
Information provided by (Responsible Party):
Ludwig Institute for Cancer Research

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Terminated
  Actual Primary Completion Date : March 2016
  Actual Study Completion Date : August 29, 2017

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 April 17, 2018